FDA monitoring 20 drugs at risk of shortage due to coronavirus
As part of its efforts to ensure the supply of medical products from China during the ongoing coronavirus (Covid-19) outbreak, the FDA has identified 20 drugs that are made in or produced solely from active pharmaceutical ingredients (APIs) sourced from China.
In a statement to Focus, FDA spokesperson Stephanie Caccomo said the agency has been in contact with the companies that make the 20 products and that “none of these firms has reported any shortage to date.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
